Loading...
•
Dec 31, 2022
Replimune Q3 2023 Earnings Report
Reported financial results for the fiscal third quarter and provided a business update.
Key Takeaways
Replimune reported its Q3 financial results, highlighting a strengthened balance sheet with $259 million raised through a public offering, extending the cash runway into H2 2025. Key clinical trial milestones were achieved, including target enrollment in the IGNYTE trial and anticipation of topline data from the CERPASS trial in Q3 2023.
Strengthened balance sheet with $259 million raised through an upsized public offering, extending cash runway into H2 2025.
Topline data from the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC) expected in Q3 2023.
Target enrollment of 125 patients achieved in the IGNYTE clinical trial cohort of RP1 combined with Opdivo in anti-PD1 failed melanoma.
Collaboration announced with Roche for signal finding studies in RP2/3 in third-line colorectal cancer and first- and second-line hepatocellular carcinoma.
Replimune
Replimune
Forward Guidance
Replimune believes that existing cash, cash equivalents and short-term investments, as of December 31, 2022, will enable the Company to fund operations into the second half of calendar year 2025.